Integer to Highlight Innovations in Neuromodulation, Next Generation of Miniaturized Active Implantable Devices During NANS 2025 Annual Meeting
Rhea-AI Summary
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization, will showcase its innovations at the North American Neuromodulation Society (NANS) Annual Meeting from January 30 to February 1, 2025, in Orlando, Florida. At booth #213, Integer will present its latest advancements in neuromodulation and miniaturized active implantable medical devices (AIMDs).
The company will highlight its Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology, which offers industry-leading battery runtime and can fully recharge in as little as 30 minutes. Integer aims to demonstrate its capabilities as a strategic partner for OEMs, focusing on accelerating and de-risking the path to market for novel implantable medical devices through their expertise in critical implantable technologies.
Positive
- Showcasing advanced Xcellion® Gen 3 FC battery technology with 30-minute full recharge capability
- Strategic positioning in the growing neuromodulation market
Negative
- None.
~ Attendees Invited to Visit Integer at Booth #213 ~
PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Orlando, Florida, from Jan. 30 – Feb. 1, 2025.
NANS attendees are invited to visit booth #213 to learn more about how Integer can serve as a strategic partner of choice in amplifying customers’ innovation and increasing speed to market. More specifically, Integer will showcase its latest innovations and expanded capabilities in neuromodulation to enable the next generation of miniaturized active implantable medical devices (AIMDs).
“Through miniaturization, Integer is creating the next generation of differentiated platform technologies to accelerate and de-risk OEMs’ path to market for novel implantable medical devices,” said Jim Stephens, President, Cardiac Rhythm Management & Neuromodulation. “Our broad expertise in critical implantable technologies—from batteries to fully integrated implantable pulse generator systems—uniquely positions Integer to deliver advancements in miniaturized AIMD technologies and help enable our customers’ future therapies. We look forward to discussing this and more at NANS.”
During NANS, attendees can also learn more about Integer’s Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology. Xcellion Gen 3 FC delivers best in class battery runtime and full re-charges in as little as 30 minutes.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Andrew Senn | Kelly Butler |
| andrew.senn@integer.net | kelly.butler@integer.net |
| 763.951.8312 | 469.731.6617 |
FAQ
What new technology will Integer (ITGR) showcase at NANS 2025?
When and where is Integer (ITGR) presenting at NANS 2025?
What are the key features of Integer's (ITGR) Xcellion Gen 3 FC battery?
How is Integer (ITGR) supporting OEM medical device development?
